| 摘要 |
Described is the use of a cGMP-PDE5 inhibitor for the manufacture of a medicament for the treatment of neuropathy, with the proviso that the inhibitor is not a: i) substituted 5-(3-pyridyl)pyrazolo[4,3-d]pyrimidin-7-one, ii) substituted 2-(3-pyridyl)-4a,5-dihydroimidazo[5,1-f][1,2.4]triazin-4(3H)-one, or iii) substituted 2-phnylpurin-6-one or a substituted 2-(3-pyridyl)-purin-6-one for treating peripheral diabetic neuropathy.
|
